Strata Critical Medical, Inc.
NASDAQ:SRTAAirlines, Airports & Air Services
-$0.03 today
- Market cap
- $443.03M
- Beta
- 2.20
- P/E (TTM)
- 9.7
- EPS (TTM)
- $0.60
Volume 0.99M
Average 0.91M
SRTA Operating Margin
Operating income as a percentage of revenue, showing the profitability of core operations.
Strata Critical Medical, Inc.NASDAQ: SRTA
Operating Margin · Q1 FY2026 · quarter ended Mar 2026
Operating margin widens to -2.5%
Operating margin was -2.5% in Q1 FY2026, up 11.4 pp from a year earlier. On a trailing-twelve-month basis it was -6.0%, up 6.6 pp year over year. Over 3 fiscal years it widened by 31.7 pp.
Context
- Operating margin widened in 3 of the last 3 fiscal years.
- FY2025 was the highest level in the 4 fiscal years shown.
What to watch
Whether operating margin reaches the consensus estimate from 3 analysts of -2.0% for the fiscal year ending Dec 2026, up from -5.0% in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -2.5%+1.8 pp QoQ
- Last fiscal yearDec 2025
- -5.0%+8.7 pp YoY
- LTMMar 2026
- -6.0%+6.6 pp YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +11.4 pp | +4.4 pp | -7.1 pp |
| 1 year | +8.7 pp | +3.0 pp | -5.7 pp |
| 3 years | +31.7 pp | +9.5 pp | -22.2 pp |
| 5 years | — | — | |
| 10 years | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Operating Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- -5.0%
- Year-over-year change
- +8.7pp
| Period | Period end | Operating Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | -5.0% | +8.7pp |
| FY2024 | 2024-12-31 | -13.6% | +16.6pp |
| FY2023 | 2023-12-31 | -30.3% | +6.4pp |
| FY2022 | 2022-12-31 | -36.6% | +11.1pp |
| FY2021 | 2021-09-30 | -47.7% | — |
Operating Margin vs competitors
How SRTA compares with its peers on the latest reported figures
- SRTA's LTM Mar 2026 operating margin of -6.0% is the 7th highest of the 10 companies compared; the peer median is -2.1%.
- Its year-over-year change of +6.6 pp is the 3rd highest of 10, against a peer median of -0.0 pp.
- Over three fiscal years its change of +31.7 pp compares with a peer median of -3.1 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Feb 2026 | 13.4% | +0.2 pp | -1.9 pp | |
| LTM Mar 2026 | 3.8% | -6.1 pp | -3.1 pp | |
| LTM Mar 2026 | 1.4% | -0.5 pp | +2.5 pp | |
| LTM Mar 2026 | -1.8% | +1.9 pp | +7.9 pp | |
| LTM Mar 2026 | -2.1% | -0.0 pp | -15.1 pp | |
| LTM Apr 2026 | -2.1% | -10.4 pp | -8.1 pp | |
SRTAStrata Critical Medical, Inc. | LTM Mar 2026 | -6.0% | +6.6 pp | +31.7 pp |
| LTM Mar 2026 | -11.1% | +10.1 pp | -9.4 pp | |
| LTM Mar 2026 | -21.4% | +38.4 pp | -12.9 pp | |
| LTM Mar 2026 | -48.7% | -25.1 pp | +126.4 pp | |
| FY2025 | — | — | — | |
| Peer median (excluding SRTA) | -2.1% | -0.0 pp | -3.1 pp | |
Competitors are the stored peer set for SRTA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Sep 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 50.53M | 146.12M | 225.18M | 248.69M | 197.14M |
| Cost of Revenue | 40.01M | 123.85M | 183.06M | 189.77M | 158.82M |
| Gross Profit | 10.52M | 22.28M | 42.12M | 58.92M | 38.33M |
| Gross Margin | 20.8% | 15.2% | 18.7% | 23.7% | 19.4% |
| Research & Development | 1.68M | 5.55M | 4.63M | 3.18M | 3.05M |
| Selling, General & Admin | 32.93M | 70.26M | 105.61M | 89.66M | 45.08M |
| Operating Expenses | 34.61M | 75.8M | 110.24M | 92.85M | 48.13M |
| Depreciation & Amortization | 596K | 5.73M | 7.11M | 5.96M | 6.9M |
| EBITDA | (43.1M) | (22.31M) | (50.43M) | (21.6M) | (13.17M) |
| EBITDA Margin | -85.3% | -15.3% | -22.4% | -8.7% | -6.7% |
| Operating Income | (24.09M) | (53.53M) | (68.12M) | (33.93M) | (9.81M) |
| Operating Margin | -47.7% | -36.6% | -30.3% | -13.6% | -5.0% |
| Interest Income | 460K | 3.43M | 8.44M | 7.21M | 4.24M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | (19.6M) | 25.5M | 10.58M | 6.36M | (10.26M) |
| Income Before Tax | (43.7M) | (28.03M) | (57.54M) | (27.56M) | (20.07M) |
| Pre-Tax Margin | -86.5% | -19.2% | -25.6% | -11.1% | -10.2% |
| Income Tax Expense | (3.64M) | (772K) | (1.47M) | (255K) | 0 |
| Net Income | (40.05M) | (27.26M) | (56.08M) | (27.31M) | (15.65M) |
| Net Margin | -79.3% | -18.7% | -24.9% | -11.0% | -7.9% |
| EPS (Basic) | (0.57) | (0.38) | (0.76) | (0.35) | (0.19) |
| EPS (Diluted) | (0.57) | (0.38) | (0.76) | (0.35) | (0.19) |
| Weighted Avg Shares | 70.1M | 71.24M | 73.52M | 77.5M | 82.45M |
| Weighted Avg Shares (Diluted) | 70.1M | 71.24M | 73.52M | 77.5M | 82.45M |
Strata Critical Medical, Inc.
NASDAQ:SRTA
Intrinsic Alpha fair value
Locked
Current Price
$4.96
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.